Document:

Exhibit 10.2
                                    AGREEMENT

         This Agreement made as of the 19th day of October,  2004, by and
between  Friendly Ice Cream  Corporation, a Massachusetts corporation
(the "Company"), and _______________ ("Employee").

         WHEREAS, Employee is an executive of the Company, currently serving as
its _____________________;

         WHEREAS, the Board of Directors (the "Board") of the Company believes
that appropriate steps should be taken to reinforce and encourage the continued
attention and dedication of Employee to the company without distraction
notwithstanding the fact that the Company could be subject to a change of
control, although no such transaction is currently being negotiated, and that
such possibility, and the uncertainty and questions which it may raise among
management, may result in the departure or distraction of key management
personnel to the detriment of the Company; and

         WHEREAS, as an inducement to Employee to continue in employment with
the Company, and in consideration of Employee agreeing to keep Company
information confidential and not to compete with the Company in the event
Employee's employment is terminated and providing the Company with a release of
any potential claims, the Company agrees that Employee shall receive a similar
release from the Company and the compensation set forth in this Agreement as a
cushion against the financial and career impact on Employee in the event
Employee's employment with the Company is terminated without cause if there is a
change of control.

         NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements hereinafter set forth and intending to be legally bound
hereby, the parties hereto agree as follows:

         1.       Definitions

                  "Affiliate" shall have the respective meaning ascribed to such
term in Rule 12b-2 of the General Rules and Regulations under the Exchange Act.

                  "Base Compensation" shall mean the sum of (i) the annualized
base rate of salary being paid to Employee in all capacities with the Company,
and its Affiliates, as reported for Federal income tax purposes on Form W-2,
together with any and all salary reduction authorized amounts under any of the
Company's benefit plans or programs, on the last day of the preceding calendar
year, or if higher, the actual date of the Change of Control, and (ii) the
Executive's average bonus for the preceding three (3) calendar years.

                  "Board" shall mean the board of directors of the Company.

                  "Cause" shall mean (1) misappropriation of funds, (2) habitual
insobriety or substance abuse, (3) conviction of a crime involving moral
turpitude, or (4) gross negligence in the performance of duties, which gross
negligence has had a material adverse effect on business, operations, assets,
properties or financial condition of the Company and its Subsidiaries taken as a
whole.

<PAGE>

                  "Change of Control"  means the  occurrence  of any of the
following  events with  respect to the Company:

                  (i)   any "person" (as such term is used in Sections 13(d) and
14(d) of the Exchange Act), other than one or more Permitted Holders, is or
becomes the "beneficial owner" (as defined in Rules 13d-3 and 13d-5 under the
Exchange Act), directly or indirectly, of 50% or more of the total voting power
of the Voting Stock of the Company;

                  (ii)  during any period of two consecutive years, individuals
who at the beginning of such period constituted the Board of Directors of the
Company (together with any new directors whose election by such Board of
Directors or whose nomination for election by the shareholders of the Company
was approved by a vote of a majority of the directors of the Company then still
in office who were either directors at the beginning of such period or whose
election or nomination for election was previously so approved) cease for any
reason to constitute a majority of the Board of Directors of the Company then in
office;

                  (iii) any sale, lease, exchange or other transfer (in one
transaction or a series of related transactions) of all, or substantially all,
the assets of the Company to any Person or group of Persons (other than to any
Wholly Owned Subsidiary of the Company);

                  (iv)  the Company merges or consolidates with or into another
Person or another Person merges with or into the Company, and in any such case,
the securities of the Company that are outstanding immediately prior to such
transaction and that represent 100% of the voting power of the Voting Stock of
the Company are changed into or exchanged for cash, securities or property,
unless pursuant to such transaction such securities of the Company are changed
into or exchanged for, in addition to any other consideration, securities of the
surviving corporation that represent, immediately after such transaction, at
least a majority of the aggregate voting power of the Voting Stock of the
surviving Person or transferee; or

                  (v)   the adoption of a plan of liquidation of the Company.

[Hopkins Only: (vi) The Company ceases to manage or operate a retail sales
component of its business operations.]

                  For purposes of the definition of Change of Control, the term
"Permitted Holders" means Donald N. Smith and/or the Company's then existing
senior management and their respective Affiliates. Notwithstanding the
foregoing, in no event shall a transaction described in clause (iii) or (iv)
between the Company and an entity in which the Employee has a substantial equity
interest constitute a Change of Control. The term "Voting Stock" of the Company
means all classes of capital stock of the Company then outstanding and normally
entitled to vote in the election of directors.

                                       2
<PAGE>

                  "Code" shall mean the Internal Revenue Code of 1986, as
amended.

                  "Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended.

                  "Severance Period" shall mean the [two (2) year for Hoagland,
one (1) year for Green, Hopkins, Pastore and Ulrich] period after Employee's
Termination of Employment.

                  "Termination Date" shall mean the date of receipt of the
Notice of Termination described in Section 2 hereof or any later date specified
therein, as the case may be.

                  "Termination of Employment" shall mean the termination of
Employee's active employment relationship with the Company.

                  "Termination following a Change of Control" shall mean a
Termination of Employment within two years after a Change of Control either:

                  (i) initiated by the Company for any reason other than (x)
Employees' continuous illness, injury or incapacity for a period of six
consecutive months or (y) for "Cause" or

                  (ii) initiated by Employee upon one or more of the following
occurrences:

                       (A)      any failure of the Company to comply with
                                and satisfy any of the terms of this
                                Agreement;

                       (B)      any significant reduction by the Company of
                                the authority, duties, reporting
                                responsibilities or job responsibilities of
                                Employee, including any such reduction
                                attributable to the fact that the Company is
                                no longer a public company or has become a
                                subsidiary of another company;

                       (C)      any removal by the Company of Employee from
                                the employment grade, compensation level or
                                officer positions which Employee holds as of
                                the effective date hereof except in
                                connection with promotions to higher office;

                       (D)      the requirement that Employee undertake
                                business travel to an extent substantially
                                greater than is reasonable and customary for
                                the position Employee holds; or

                       (E)      the moving of the principal office of the
                                Company to which Employee is assigned by
                                more than 50 miles from its location on the
                                date of this Agreement.

         2.       Notice of Termination. Any Termination of Employment shall be
communicated by a Notice of Termination to the other party hereto given in
accordance with Section 16 hereof. For purposes of this Agreement, a "Notice of
Termination" means a written notice which (i) indicates the specific reasons for
the termination, (ii) briefly summarizes the facts and circumstances deemed to
provide a basis for termination of Employee's employment, and (iii) if the
Termination Date is other than the date of receipt of such notice, specifies the
Termination Date (which date shall not be more than 15 days after the giving of
such notice).

                                       3
<PAGE>

         3.       Severance Compensation upon Termination. Subject to the
provisions of Section 10 hereof and the paragraph of this Section 3, in the
event of Employee's Termination following a Change of Control, Employee shall be
entitled to receive the following payments and benefits from the Company:

                  (a) Within 15 days after the Termination Date, Employee shall
receive a lump sum cash payment equal to (i) the Employee's Base Compensation
times the number of years in the Severance Period; plus (ii) a pro-rated amount
of the annual incentive bonus that Employee would have received for the year of
termination. The pro-rated bonus shall be computed as 100% of the Employee's
average bonus for the three (3) calendar years preceding the Employee's
Termination of Employment, multiplied by a fraction (x) the numerator of which
is the number of days in such year preceding Employee's Termination Date, and
(y) the denominator of which is 365.

                  (b) The Company shall continue to provide benefits under the
Company's then current health plan (subject to changes made pursuant to
amendments of general application adopted from time to time) for Employee and
his spouse or dependents for the Severance Period on the same basis as if
Employee had continued to be employed during that period, or pay Employee cash
in lieu of such coverage in an amount equal to Employee's after-tax cost of
continuing such coverage.

                  (c) During the Severance Period, the Company shall reimburse
Employee for the cost of outplacement assistance services, which shall be
provided by an outplacement agency selected by Employee. The Company shall
reimburse Employee within 15 days following the date on which the Company
receives proof of payment of such expense.

                  Notwithstanding the foregoing, (i) any payment or benefit
under this Agreement shall be subject to such limitations as may be required to
comply with Section 409A of the Code, and (ii) no payments or benefits shall be
provided under this Agreement unless Employee executes, and does not revoke, an
effective written release, complying with all state and federal requirements
(the "Release"), of any and all claims against the Company and all related
parties with respect to all matters arising out of Employee's employment by the
Company (other than entitlements under the terms of this Agreement or under any
other plans or programs of the Company in which Employee participated and under
which Employee has accrued or become entitled to a benefit) or the termination
thereof. On the day following the expiration of the revocation period for the
Release, the Company shall provide Employee with a mutual release releasing
Employee from any and all claims arising out of Employee's employment with the
Company.

                                       4
<PAGE>

         4.       Other Payments and Indemnifications. The payment due under
Section 3 hereof shall be in addition to and not in lieu of any payments or
benefits due to Employee under any other plan, policy or program of the Company
except that Employee shall not receive any benefits under any other severance
plan of the Company and the pro-rated bonus under clause 3(a)(ii) above shall be
in lieu of any pro-rated annual incentive bonus to which Employee would
otherwise be entitled for the year of termination. In addition, Employee shall
continue to be covered by any policy of insurance providing indemnification
rights for service as an officer and director of the Company and to all other
rights to indemnification provided by the Company, in each case at least as
favorable as applicable to him on the date of this Agreement.

         5.       Enforcement.

                  (a) In the event that the Company shall fail or refuse to make
payment of any amounts due Employee under Section 3, 4 and 10 hereof with the
respective time periods, provided therein, the Company shall pay to Employee, in
addition to the payment of any other sums provided in this Agreement, interest,
compounded daily, on any amount remaining unpaid from the date payment is
required under Section 3, 4, and 10, as appropriate, until paid to Employee, at
the rate from time to time announced by Bank of America, N.A. as its "prime
rate" plus 2%, each change in such rate to take effect on the effective date of
the change in such prime rate.

                  (b) It is the intent of the parties that Employee not be
required to incur any expenses associated with the enforcement of his rights
under this Agreement by arbitration, litigation or other legal action because
the cost and expense thereof would substantially detract from the benefits
intended to be extended to Employee hereunder. Accordingly, the Company shall
pay Employee on demand the amount necessary to advance to or reimburse Employee
in full for all expenses (including all attorneys' fees and legal expenses)
incurred by Employee in good faith attempting to enforce any of the obligations
of the Company under this Agreement, without regard to outcome.

         6.       No Mitigation. Employee shall not be required to mitigate the
amount of any payment or benefit provided for in this Agreement by seeking other
employment or otherwise, nor shall the amount of any payment or benefit provided
for herein be reduced by any compensation earned by other employment or
otherwise.

         7.       Non-exclusivity of Rights. Except as provided in Section 4,
nothing in this Agreement shall prevent or limited Employee's continuing or
future participation in or rights under any benefit, bonus, incentive or other
plan or program provided by the Company or any of its Subsidiaries or Affiliates
and for which Employee may qualify.

         8.       No Set-Off. The Company's obligation to make the payments
provided for in this Agreement and otherwise to perform its obligations
hereunder shall not be affected by any circumstances, including, without
limitation, any set-off, counterclaim, recoupment, defense or other right which
the Company may have against Employee or others.

                                       5
<PAGE>

         9.       Taxes. Any payment required under this Agreement shall be
subject to all requirements of the law with regard to the withholding of taxes,
filing, making of reports and the like, and the Company shall use its best
efforts to satisfy promptly all such requirements.

10.      Certain Increases in Payment.

                  (a) Anything in this Agreement to the contrary
notwithstanding, in the event that it shall be determined that any payment or
distribution by the Company to or for the benefit of Employee, whether paid or
payable or distributed or distributable pursuant to the terms of this Agreement
or otherwise (the "Payment"), would constitute an "excess parachute payment"
within the meaning of Section 280G of the Code, Employee shall be paid an
additional amount (the "Gross-Up Payment") such that the net amount retained by
Employee after deduction of any excise tax imposed under Section 4999 of the
Code, and any federal, state and local income and employment tax and excise tax
imposed upon the Gross-Up Payment shall be equal to the Payment. For purposes of
determining the amount of the Gross-Up Payment, Employee shall be deemed to pay
federal income tax and employment taxes at the highest marginal rate of federal
income and employment taxation in the calendar year in which the Gross-Up
Payment is to be made and state and local income taxes at the highest marginal
rate of taxation in the state and locality of Employee's residence (or, if
greater, the state and locality in which Employee is required to file a
nonresident income tax return with respect to the Payment) on the Termination
Date, net of the maximum reduction in federal income taxes that may be obtained
from the deduction of such state and local taxes.

                  (b) All determinations to be made under this Section 10 shall
be made by the Company's independent public account immediately prior to the
Change of Control or, if such firm declines to act, such other independent
public accountant as may be agreed to by the Company and the Employee (the
"Accounting Firm"), which firm shall provide its determinations and any
supporting calculations both to the Company and Employee within ten days of the
Termination Date. Any such determination by the Accounting Firm shall be binding
upon the Company and Employee. Within five days after the Accounting Firm's
determination, the Company shall pay (or cause to be paid) or distribute (or
cause to be distributed) to or for the benefit of Employee such amounts as are
then due to Employee under this Agreement.

                  (c) Employee shall notify the Company in writing of any claim
by the Internal Revenue Service that, if successful, would require the payment
by the Company of the Gross-Up Payment. Such notification shall be given as soon
as practicable but no later than ten business days after Employee knows of such
claim and shall apprise the Company of the nature of such claim and the date on
which such claim is requested to be paid. Employee shall not pay such claim
prior to the expiration of the thirty day period following the date on which he
give such notice to the Company (or such shorter period ending on the date that
any payment of taxes with respect to such claim is due). If the Company notifies
Employee in writing prior to the expiration of such period that it desires to
contest such claim, Employee shall:

                  (i)   give the Company any information reasonably requested by
                        the Company relating to such claim;

                                       6
<PAGE>

                  (ii)  take such action in connection with contesting such
                        claim as the Company shall reasonably request in writing
                        from time to time, including, without limitation,
                        accepting legal representation with respect to such
                        claim by an attorney reasonably selected by the Company;

                  (iii) cooperate with the Company in good faith in order to
                        effectively contest such claim; and

                  (iv)  permit the Company to participate in any proceedings
                        relating to such claim;

provided, however, that the Company shall bear and pay directly all costs and
expenses (including additional interest and penalties) incurred in connection
with such contest and shall indemnify and hold Employee harmless, on an
after-tax basis, for any Excise Tax, income tax or employment tax, including
interest and penalties, with respect thereto, imposed as a result of such
representation and payment of costs and expenses. Without limitation on the
foregoing provisions of this Section 10, the Company shall control all
proceedings taken in connection with such contest and, at its sole option, may
pursue or forego any and all administrative appeals, proceedings, hearing and
conferences with the taxing authority in respect of such claim and may, at its
sole option, either direct Employee to pay the tax claimed and sue for a refund
or contest the claim in any permissible manner, and Employee agrees to prosecute
such contest to a termination before any administrative tribunal, in a court of
initial jurisdiction and in one or more appellate courts, as the Company shall
determine, provided further, however, that if the Company directs Employee to
pay such claim and sue for a refund the Company shall advance the amount of such
payment to Employee, on an interest-fee basis and shall indemnify and hold
Employee harmless, on an after-tax basis, from any Excise Tax, income tax or
employment tax, including interest or penalties with respect thereto, imposed
with respect to such advance or with respect to any imputed income with respect
to such advance; and provided further that any extension of the statute of
limitations relating to payment of taxes for the taxable year of Employee with
respect to which such contested amount is claimed to be due is limited solely to
such contested amount. Furthermore, the Company's control of the contest shall
be limited to issues with respect to which a Gross-Up Payment would be payable
hereunder and Employee shall be entitled to settle or contest, as the case may
be, any other issue raised by the Internal Revenue Service or any other taxing
authority.

                  (d) If, after the receipt by Employee of an amount advanced by
the Company pursuant to this Section, Employee becomes entitled to receive any
refund with respect to such claim, Employee shall (subject to the Company's
complying with the requirements of this Section) promptly pay to the Company the
amount of such refund (together with any interest paid or credited thereon after
taxes applicable thereto). If, after the receipt by Employee of an amount
advanced by the Company pursuant to this Section, a determination is made that
Employee shall not be entitled to any refund with respect to such claim and the
Company does not notify Employee in writing of its intent to contest such denial
of refund prior to the expiration of thirty days after such determination, then
such advance shall be forgiven and shall not be required to repaid and the
amount of such advance shall offset, to the extent thereof, the amount of
Gross-Up Payment required to be paid.

                                       7
<PAGE>

                  (e) All of the fees and expenses of the Accounting Firm in
performing the determinations referred to in this Section shall be borne solely
by the Company. The Company agrees to indemnify and hold harmless the Accounting
Firm of and from any and all claims, damages and expenses resulting from or
relating to its determinations pursuant to this Section, except for claims,
damages or expenses resulting from the gross negligence or willful misconduct of
the Accounting Firm.

         11.      Confidential Information. Employee recognizes and acknowledges
that, by reason of his employment by and service to the Company, he has had and
will continue to have access to confidential information of the Company and its
affiliates, including, without limitation, information and knowledge pertaining
to the products and services offered, innovations, designs, ideas, plans, trade
secrets, proprietary information, distribution and sales methods and systems,
sales and profit figure, customer and client lists, and relationships between
the Company and its affiliates and other distributors, customers, clients,
suppliers and others who have business dealings with the Company and its
affiliates ("Confidential Information"). Employee acknowledges that such
Confidential Information is a valuable and unique asset and covenants that he
will not, either during or after his employment by the Company, disclose any
such Confidential Information to any person for any reason whatsoever without
the prior written authorization of the Board, unless such information is in the
public domain through no fault of Employee or except as may be required by law
or in a judicial or administrative proceeding. In the event that Employee is
required to disclose any of the Company's Confidential Information, Employee
shall provide reasonable notice to the Company and shall provide reasonable
cooperation with any efforts of the Company to oppose such disclosure.

         12.      Non-Competition.

                  (a) During his employment by the Company and for a period of
one year thereafter unless acting with the prior written consent of the Board,
Employee shall not, directly or indirectly, own, manage, operate, join, control,
finance or participate in the ownership, management, operation, control or
financing of, or be connected as an officer, director, employee, partner,
principal, agent, representative, consultant or otherwise with or use or permit
his name to be used in connection with, any business or enterprise in the family
dining segment. Employee also shall not, directly or indirectly, during such
period (a) solicit or divert business from, or attempt to convert any client,
account or customer of the Company or any of its affiliates, whether existing at
the date hereof or acquired during Employee's employment nor (b) following
Employee's employment, solicit or attempt to hire or hire any then employee of
the Employer or of any of its affiliates.

                  (b) The foregoing restriction shall not be construed to
prohibit the ownership by Employee of less than five percent (5%) of any class
of securities of any corporation in the family dining segment having a class of
securities registered pursuant to the Securities Exchange Act of 1934, provided
that such ownership represents a passive investment and that neither Employee
nor any group of persons including Employee in any way, either directly or
indirectly, manages or exercises control of any such corporation, guarantees any
of its financial obligations, otherwise takes any part in its business, other
than exercising his rights as a shareholder, or seeks to do any of the
foregoing.

                                       8
<PAGE>

         13.      Equitable Relief.

                  (a) Employee acknowledges that the restrictions contained in
Sections 11 and 12 hereof are reasonable and necessary to protect the legitimate
interests of the Company and its affiliates, that the Company would not have
entered into this Agreement in the absence of such restrictions, and that any
violation of any provision of those Sections will result in irreparable injury
to the Company. Employee represents that his experience and capabilities are
such that the restrictions contained in Section 12 hereof will not prevent
Employee from obtaining employment or otherwise earning a living at the same
general level of economic benefit as is currently the case. Employee further
represents and acknowledges that (i) he has been advised by the Company to
consult his own legal counsel in respect of this Agreement, and (ii) that he has
had full opportunity, prior to execution of this Agreement, to review thoroughly
this Agreement with this counsel.

                  (b) Employee agrees that the Company shall be entitled to
preliminary and permanent injunctive relief, without the necessity of proving
actual damages, as well as an equitable accounting of all earnings, profits and
other benefits arising from any violation of Sections 11 or 12 hereof, which
rights shall be cumulative and in addition to any other rights or remedies to
which the Company may be entitled. In the event that any of the provisions of
Sections 11 or 12 hereof should ever be adjudicated to exceed the time,
geographic, service, or other limitations permitted by applicable law in any
jurisdiction, then such provisions shall be deemed reformed in such jurisdiction
to the maximum time, geographic, service, or other limitations permitted by
applicable law.

                  (c) Employee irrevocably and unconditionally (i) agrees that
any suit, action or other legal proceeding arising out of Sections 11 or 12
hereof, including without limitation, any action commenced by the Company for
preliminary and permanent injunctive relief or other equitable relief, may be
brought in the United States District Court for the District of Massachusetts,
or if such court does not have jurisdiction or will not accept jurisdiction, in
any court of general jurisdiction in Hampden County, Massachusetts, (ii)
consents to the non-exclusive jurisdiction of any such court it any such suit,
action or proceeding, and (iii) waives any objection which Employee may have to
the laying of venue of any such suit, action or proceeding in any such court.
Employee also irrevocably and unconditionally consents to the service of any
process, pleadings, notices or other papers in a manner permitted by the notice
provisions of Section 16, hereof.

         14.      Term of Agreement. The term of this Agreement shall be for
three years from the date hereof and shall be automatically renewed for
successive one-year periods unless the Company notifies Employee in writing that
this Agreement will not be renewed at least sixty days prior to the end of the
current term; provided, however, that (i) after a Change of Control during the
term of this Agreement, this Agreement shall remain in effect until all of the
obligations of the parties hereunder are satisfied, and (ii) this Agreement
shall terminate if, prior to a Change of Control, the employment of Employee
with the Company or any of its subsidiaries, as the case may be, shall terminate
for any reason; provided, however, that if the Employee is involuntarily
terminated by the Company in contemplation of a Change of Control which occurs
within three months after such termination of employment, this clause (ii) shall
not apply and such termination shall be deemed to be a Termination following a
Change of Control.

                                       9
<PAGE>

         15.      Successor Company. The Company shall require any successor or
successors (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business and/or assets of the
Company, by agreement in form and substance satisfactory to Employee, to
acknowledge expressly that this Agreement is binding upon and enforceable
against the Company in accordance with the terms hereof, and to become jointly
and severally obligated with the Company to perform this Agreement in the same
manner and to the same extent that the Company would be required to perform if
no such succession or successions had taken placed. Failure of the Company to
obtain such agreement prior to the effectiveness of any such succession shall be
a breach of this Agreement. As used in this Agreement, the Company shall mean
the Company as herein before defined and any such successor or successors to its
business and/or assets, jointly and severally.

         16.      Notice. All notices and other communications required or
permitted hereunder or necessary or convenient in connection herewith shall be
in writing and shall be delivered personally or mailed by registered or
certified mail, return receipt requested, or by overnight express courier
services, as follows:

         If to the Company, to:

                  Friendly Ice Cream Corporation
                  1855 Boston Road
                  Wilbraham, MA 01095

         With a copy to:

                  Office of the General Counsel
                  Friendly Ice Cream Corporation
                  1855 Boston Road
                  Wilbraham, MA  01095

         If to Employee, to:

                  ----------------------------
                  ----------------------------
                  ----------------------------

or to such other names or addresses as the Company or Employee, as the case may
be, shall designate by notice to the other party hereto in the manner specified
in this Section; provided, however, that if no such notice is given by the
Company following a Change of Control, notice at the last address of the Company
or to any successor pursuant to Section 16 hereof shall be deemed sufficient for
the purposes hereof. Any such notice shall be deemed delivered and effective
when received in the case of personal delivery, five days after deposit; postage
prepaid, with the U.S. Postal Service in the case of registered or certified
mail, or on the next business day in the case of overnight express courier
service.

                                       10
<PAGE>

         17.      Governing Law. This Agreement shall be governed by and
interpreted under the laws of the Commonwealth of Massachusetts without giving
effect to any conflict of laws provisions.

         18.      Contents of Agreement, Amendment and Assignment.

                  (a) This Agreement supercedes all prior agreements, set forth
the entire understanding between the parties hereto with respect to the subject
matter hereof and cannot be changed, modified, extended or terminated except
upon written amendment executed by Employee and approved by the Board and
executed on the Company's behalf by a duly authorized officer; provided,
however, that except as stated in Section 4, this Agreement is not intended to
supercede or alter Employee's rights under any compensation, benefit plan or
program, unless specifically modified hereunder, in which Employee participated
and under which Employee retains a right to benefits. The provisions of this
Agreement may provide for payments to Employee under certain compensation or
bonus plans under circumstances where such plans would not provide for payment
thereof. It is the specific intention of the parties that the provisions of this
Agreement shall supercede any provisions to the contrary in such plans, and such
plans shall be deemed to have been amended to correspond with this Agreement
without further action by the Company or the Board.

                  (b) Nothing in this Agreement shall be construed as giving
Employee any right to be retained in the employ of the Company.

                  (c) All of the terms and provisions of this Agreement shall be
binding upon and inure to the benefit of and enforceable by the respective
heirs, representatives, successors and assigns of the parties hereto, except
that the duties and responsibilities of Employee and the Company hereunder shall
not be assignable in whole or in part by the Company.

         19.      Severability. If any provision of this Agreement or
application thereof to anyone or under any circumstances shall be determined to
be invalid or unenforceable, such invalidity or unenforceability shall not
affect any other provisions or applications of this Agreement which can be given
effect without the invalid or unenforceable provision or application.

         20.      Remedies Cumulative; No Waiver. No right conferred upon
Employee by this Agreement is intended to be exclusive of any other right or
remedy, and each and every such right or remedy shall be cumulative and shall be
in addition to any other right or remedy given hereunder or now or hereafter
existing at law or in equity. No delay or omission by Employee in exercising any
right, remedy or power hereunder or existing at law or in equity shall be
construed as a waiver thereof, including, without limitation, any delay by
Employee in delivering a Notice of Termination pursuant to Section 2 hereof
after an event has occurred which would, if Employee had resigned, have
constituted a termination following a Change of Control pursuant to Section 1 of
this Agreement.

                                       11
<PAGE>

         21.      Miscellaneous. All section headings are for convenience only.
This Agreement may be executed in several counterparts, each of which is an
original. It shall not be necessary in making proof of this Agreement or any
counterpart hereof to produce or account for any of the other counterparts.

         IN WITNESS WHEREOF, the undersigned, intending to be legally bound,
have executed this Agreement as of the date first above written.

                                         Friendly Ice Cream Corporation

                                         By:
                                            ------------------------------------

------------------------------------        ------------------------------------
Witness                                     Employee

                                       12
<PAGE>

      Schedule to Change of Control Agreement Relating to Change of Control

The following is a list of the Company's employees who are party to the Change
of Control Agreement, the form of which is filed herewith:

                  Paul V. Hoagland
                  Kenneth D. Green
                  Gregory A. Pastore
                  Garrett J. Ulrich
                  Timothy B. HopkinsExhibit 10.1

                              SETTLEMENT AGREEMENT

      This Settlement  Agreement  ("Agreement")  is made this third day of April
2007, by and between  VaxGen,  Inc.  ("VaxGen") and the Department of Health and
Human  Services,  including  the  Office  of  Public  Health  Emergency  Medical
Countermeasures  ("OPHEMC")  within the Office of the  Assistant  Secretary  for
Preparedness and Response,  and the National Institute of Allergy and Infectious
Diseases  ("NIAID")  within the  National  Institutes  of Health  (collectively,
"HHS").

      VaxGen is a corporation  organized under the laws of the State of Delaware
with its  principal  place of  business  at 1000  Marina  Boulevard,  Suite 200,
Brisbane,  California  94005-1841.  HHS is an Executive Department of the United
States  Government  with its  headquarters  at 200  Independence  Avenue,  S.W.,
Washington,  D.C.  20201.  The  signatories  to this Agreement  hereinafter  are
referred  to  singularly  or  collectively  as,  respectively,  a "Party" or the
"Parties."

      This  Agreement  is made  as a  compromise  between  the  Parties  for the
complete and final settlement of the dispute and litigation  before the Civilian
Board of Contract  Appeals  ("CBCA"),  known as VaxGen,  Inc. v.  Department  of
Health  and  Human   Services,   CBCA  No.  674,   arising  under  Contract  No.
HHSO100200500001C  ("OPHEMC Contract"),  as well as any and all other claims and
disputes  between  the  Parties  related to the OPHEMC  Contract,  Contract  No.
N01-Al-25494 ("First NIAID Contract"), and/or Contract No. N01-Al-30053 ("Second
NIAID Contract").

                                    PREAMBLE

      WHEREAS,  in September 2002, NIAID awarded VaxGen the First NIAID Contract
for research and development  associated with a new anthrax vaccine.  VaxGen has
completed performance of the First NIAID Contract.

                                       1
<PAGE>

      WHEREAS, in September 2003, NIAID awarded VaxGen the Second NIAID Contract
for further research and development associated with the new anthrax vaccine.

      WHEREAS,  in  November  2004,  the  Office  of  Research  and  Development
Coordination  within  the HHS  Office of Public  Health  Emergency  Preparedness
awarded VaxGen the OPHEMC Contract for the development,  production and delivery
of the new anthrax vaccine.  During the course of contract  performance,  and as
the  result of an agency  reorganization,  administration  of the  contract  was
transferred to OPHEMC.

      WHEREAS,  on March 30, 2006,  VaxGen  submitted a certified  claim to HHS,
pursuant to the Contract  Disputes Act of 1978,  for an equitable  adjustment to
the price and schedule for alleged  formal and  constructive  changes  under the
OPHEMC Contract.

      WHEREAS,  on April 21, 2006, the OPHEMC Contracting Officer issued a final
decision  denying  VaxGen's  certified  claim in its  entirety  under the OPHEMC
Contract.

      WHEREAS,  on December 19, 2006,  the OPHEMC  Contracting  Officer issued a
notice to VaxGen  terminating the OPHEMC Contract for default.  In the notice of
default  termination,  the Contracting Officer stated,  among other things, that
"[t]he supplies terminated may be purchased against VaxGen's account, and VaxGen
will be held liable for any excess  costs.  . . . The  government  reserves  all
rights and remedies  provided by law or under contract,  in addition to charging
excess costs."

      WHEREAS, on December 21, 2006, the NIAID Contracting Officer issued a Stop
Work order to VaxGen,  suspending  performance of the Second NIAID Contract.  On
January 5, 2007,  and again on March 21,  2007,  the NIAID  Contracting  Officer
extended the duration of the stop work order.

                                       2
<PAGE>

      WHEREAS,  on January 22,  2007,  the NIAID  Contracting  Officer  notified
VaxGen that the agency was  suspending  payment of a total of  $6,477,141.64  in
outstanding  invoice  payments under the Second NIAID Contract,  as an offset to
potential future VaxGen liability for excess  reprocurement costs related to the
default termination of the OPHEMC Contract.

      WHEREAS,  on February 8, 2007,  VaxGen submitted a certified claim to HHS,
pursuant to the Contract  Disputes Act of 1978,  challenging  the  suspension of
invoice payments under the Second NIAID Contract.

      WHEREAS,  on March 14,  2007,  VaxGen filed a Notice of Appeal at the CBCA
regarding the default termination of the OPHEMC Contract.

      WHEREAS, HHS and VaxGen wish to avoid the necessity,  risk, and expense of
further litigation and to resolve and settle all claims, liabilities,  disputes,
and obligations between them arising under, out of, related to, or pertaining in
any way to the First  NIAID  Contract,  the Second  NIAID  Contract,  and/or the
OPHEMC Contract (the "Claims and Disputes").

      NOW,  THEREFORE,  in  consideration of the payment,  mutual promises,  and
releases contained herein and other good and valuable consideration, the receipt
and sufficiency of which hereby are acknowledged, the Parties agree as follows:

1.0   SETTLEMENT

      1.1 HHS  shall  pay  VaxGen  Eleven  Million  Dollars  ($11,000,000)  (the
"Settlement  Funds") in full  settlement of the Claims and  Disputes.  HHS shall
make,  and VaxGen shall receive,  such payment by taking the following  actions:
(a) NIAID shall issue a bilateral modification to the Second NIAID Contract that
incorporates  by reference and attaches this  Agreement,  and that obligates the
Settlement Funds to the Second NIAID Contract;  (b) VaxGen shall submit a proper
invoice for the Settlement Funds (attached); and (c) NIAID shall authorize

                                       3
<PAGE>

payment  of the  Settlement  Funds to VaxGen  and shall  take all other  actions
necessary  to process and ensure  payment  within 30 days of NIAID's  receipt of
VaxGen's invoice for the Settlement Funds.

      1.2 HHS shall  terminate the Second NIAID Contract for the  convenience of
the Government.  To accomplish this, NIAID shall issue a bilateral  modification
to the Second NIAID  Contract that  incorporates  by reference and attaches this
Agreement,  and that  institutes the  termination  for  convenience on a no-cost
basis.

      1.3 The Parties agree that VaxGen,  and its successors,  its assigns,  and
its affiliates,  shall have the right to access and use those research  results,
reports,  and data,  relating  exclusively  to those studies where only VaxGen's
investigational  recombinant anthrax vaccine was used, developed by or on behalf
of NIAID (for example,  through the Animal  Working Group  process) prior to the
date of this Agreement. The parties further agree VaxGen shall have the right to
access and use research results, reports, and data developed by VaxGen under the
First NIAID Contract or the Second NIAID Contract.

      1.4 HHS shall convert the  termination  for default of the OPHEMC Contract
to a termination  for the  convenience of the  Government.  To accomplish  this,
OPHEMC  shall  issue  a  bilateral  modification  to the  OPHEMC  Contract  that
incorporates by reference and attaches this  Agreement,  and that institutes the
termination for convenience on a no-cost basis.

      1.5 Upon  receipt  by  VaxGen  of the  Settlement  Funds  within  the time
required by Paragraph 1.1(c), the Parties shall execute, and file with the CBCA,
a Joint  Motion to Dismiss  with  Prejudice  the Appeal  regarding  the  default
termination of the OPHEMC Contract.

      1.6 The Parties'  performance  of the  obligations  set forth herein shall
finally settle and resolve any and all claims,  demands and defenses that either
Party asserted or could have

                                       4
<PAGE>

asserted against the other Party,  arising out of, under, or in any way relating
to the Claims and Disputes.

2.0   COMPROMISE

      2.1 This  Agreement  is the  result of a  compromise  and  shall  never be
construed  as an  admission  by the  Parties of any  liability,  wrongdoing,  or
responsibility on their part or on the part of their  predecessors,  successors,
assignees,  agents,  parents,  subsidiaries,  affiliates,  attorneys,  officers,
directors, or employees.  Indeed, the Parties expressly deny any such liability,
wrongdoing, or responsibility.

      2.2 The Parties agree that this Agreement  shall not be cited or otherwise
referred to in any other  proceedings,  except as is  necessary  to enforce this
Agreement.

3.0   RELEASES

      3.1 VaxGen for itself, its predecessors,  its successors, its assigns, its
affiliates,  its  subcontractors  (of every tier), and its vendors for the first
NIAID   Contract,   the  Second  NIAID  Contract,   and  the  OPHEMC   Contract,
respectively, hereby relinquishes,  releases, waives, and forever discharges all
claims,  demands,  and  defenses of whatever  kind that it has asserted or could
have asserted  against HHS arising out of, under,  or in any way relating to the
Claims and Disputes, including without limitation (a) any unpaid costs under the
First NIAID  Contract,  (b) the certified claim dated February 8, 2007 under the
Second NIAID  Contract,  (c) the certified  claim dated March 30, 2006 under the
OPHEMC  Contract,  and (d) the CBCA appeal filed March 14, 2007 under the OPHEMC
Contract.

      3.2 HHS for itself, its predecessors, its successors, its assigns, and its
affiliates,  including NIAID and OPHEMC, hereby relinquishes,  releases, waives,
and forever discharges all claims,  demands,  and defenses of whatever kind that
it has asserted or could have asserted

                                       5
<PAGE>

against VaxGen  arising out of, under,  or in any way relating to the Claims and
Disputes, including but not limited to future excess reprocurement costs related
to the default termination of the OPHEMC Contract.

4.0   ADDITIONAL TERMS AND CONDITIONS

      4.1 This Agreement sets forth and constitutes the entire agreement between
the Parties with respect to its subject  matter and supersedes any and all prior
agreements,  understandings,  promises,  warranties, and representations made by
each to the other concerning its subject matter.  This Agreement may be modified
only by a written document signed by the Parties. No waiver of this Agreement or
any of its  promises,  obligations,  terms or  conditions  is valid unless it is
written and signed by the Party against whom the waiver is to be enforced.

      4.2 This  Agreement  may be executed in  identical  counterparts,  each of
which shall constitute an original and all of which shall constitute one and the
same Agreement.  Copies of all or part of this Agreement,  including  signatures
thereto,  which are copies or  transmitted  by facsimile or electronic  mail are
presumed valid.

      4.3  This  Agreement  is  binding  on  the  Parties,  their  predecessors,
successors,  parents,  subsidiaries,  affiliates,  assignees, agents, directors,
officers, employees, shareholders and attorneys. Each of the signatories of this
Agreement  represents  and warrants  that he/she is  authorized  to execute this
Agreement on behalf of his/her  respective  Party and by such  signature to bind
that Party to this Agreement.

      4.4 Each Party  agrees,  upon the request of the other  Party,  to execute
such  additional  documents  and  perform  such other  acts,  as are  reasonably
necessary or appropriate to accomplish the intent of the Parties as expressed in
this Agreement.

                                       6
<PAGE>

      IN WITNESS  WHEREOF,  we have  hereunto  set our hands and seals as of the
date above written.

      VAXGEN, INC.

      By:   /s/ James P. Panek
         ----------------------------
            James P. Panek
            Chief Executive Officer

      DEPARTMENT OF HEALTH AND HUMAN SERVICES

      By:   /s/ Brian K. Goodger
         ----------------------------
            Brian K. Goodger
            Contracting Officer
            HHS/OS/ASPR/OPHEMC

      By:   /s/ Barbara A. Shadrick
         ----------------------------
            Barbara A. Shadrick
            Contracting Officer
            HHS/NIH/NIAID

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]